Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Durlobactam (DUR; ETX2514) is a novel β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C, and D β-lactamases. Durlobactam restores the in vitro activity of sulbactam (SUL) against members of the Acinetobacter baumannii-A. calcoaceticus complex (ABC). Sulbactam (SUL)-durloba...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Antimicrob Agents Chemother
Prif Awduron: Sagan, Olexiy, Yakubsevitch, Ruslan, Yanev, Krassimir, Fomkin, Roman, Stone, Emily, Hines, Daniel, O’Donnell, John, Miller, Alita, Isaacs, Robin, Srinivasan, Subasree
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2020
Pynciau:
Clinical Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038258/
https://ncbi.nlm.nih.gov/pubmed/31843995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01506-19
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg